← Back to Search

Lisinopril for Preventing Urinary Side Effects in Prostate Cancer Radiotherapy

Phase < 1
Recruiting
Research Sponsored by University of Rochester
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will help determine the best dose of lisinopril for men with prostate cancer undergoing radiation, and whether the drug can help relieve urinary symptoms.

Who is the study for?
Men under 70 with non-metastatic prostate cancer who are set for radiation therapy at Wilmot Cancer Institute can join. They must be in good health, able to follow the study plan, have normal kidney and liver function, not have had pelvic radiotherapy before, and not be on lisinopril or similar drugs recently.
What is being tested?
The trial is testing different doses of Lisinopril tablets to find the best one for preventing urinary problems after radiation treatment for prostate cancer. It will also look at how Lisinopril affects certain biomarkers related to these urinary symptoms.
What are the potential side effects?
Lisinopril may cause side effects like coughing, dizziness due to low blood pressure, headaches, fatigue, nausea or problems with kidney function. Some people might experience allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean change in Expanded Prostate Index Composite score

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention groupExperimental Treatment1 Intervention
Group II: Control groupActive Control1 Intervention
Patients who receive radiation but no intervention

Find a Location

Who is running the clinical trial?

Medical College of WisconsinOTHER
631 Previous Clinical Trials
1,181,928 Total Patients Enrolled
University of RochesterLead Sponsor
869 Previous Clinical Trials
549,732 Total Patients Enrolled
1 Trials studying Urinary Tract Infection
175 Patients Enrolled for Urinary Tract Infection

Media Library

Lisinopril Tablets Clinical Trial Eligibility Overview. Trial Name: NCT05530655 — Phase < 1
Urinary Tract Infection Research Study Groups: Control group, Intervention group
Urinary Tract Infection Clinical Trial 2023: Lisinopril Tablets Highlights & Side Effects. Trial Name: NCT05530655 — Phase < 1
Lisinopril Tablets 2023 Treatment Timeline for Medical Study. Trial Name: NCT05530655 — Phase < 1
~18 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top